Skip to content

Study · Ex vivo tissue · 1984

5 results

Allogeneic bone marrow transplantation in man: in vitro activity of FTS-Zn on T-cell markers and functions.

Bordigoni P, Béné MC, Faure G, Donner M, Janot C, Dardenne M, Duheille J, Olive D

British journal of haematology1 Dec 1984Cited by 10 (Europe PMC)

PMID6097296 (opens in a new tab)DOI10.1111/j.1365-2141.1984.tb06113.x (opens in a new tab)PepBankPUB-06097296
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueActivity measurement

    In bone marrow recipients' cells, thymulin induced or modulated T-cell membrane marker expression.

    In plain wordsIn lab tests, thymulin changed T-cell membrane markers in cells from bone marrow recipients.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    MixedT-cell membrane markers
    Study

    humann = 12

    peripheral blood mononuclear cells from bone marrow recipients
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    It was demonstrated that thymulin was able to induce or modulate the expression of T-cell membrane markers, to enhance the proliferative responsiveness of lymphocytes to mitogens or allogeneic cells, and to increase mononuclear cells' natural killer activity.
    1 context sentence
    Summary · context
    The activity of this compound on peripheral blood mononuclear cells from 12 bone marrow recipients was studied in vitro.
  2. 02LabEx vivo tissueActivity measurement

    In bone marrow recipients' lymphocytes, thymulin enhanced proliferative responsiveness to mitogens.

    In plain wordsIn lab tests, thymulin increased the growth response to mitogens in bone marrow recipients' cells.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    IncreaseProliferative response to mitogens
    Study

    humann = 12

    peripheral blood mononuclear cells from bone marrow recipients
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    It was demonstrated that thymulin was able to induce or modulate the expression of T-cell membrane markers, to enhance the proliferative responsiveness of lymphocytes to mitogens or allogeneic cells, and to increase mononuclear cells' natural killer activity.
    1 context sentence
    Summary · context
    The activity of this compound on peripheral blood mononuclear cells from 12 bone marrow recipients was studied in vitro.
  3. 03LabEx vivo tissueActivity measurement

    In bone marrow recipients' lymphocytes, thymulin enhanced proliferative responsiveness to allogeneic cells.

    In plain wordsIn lab tests, thymulin increased the growth response to allogeneic cells in bone marrow recipients' cells.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    IncreaseProliferative response to allogeneic cells
    Study

    humann = 12

    peripheral blood mononuclear cells from bone marrow recipients
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    It was demonstrated that thymulin was able to induce or modulate the expression of T-cell membrane markers, to enhance the proliferative responsiveness of lymphocytes to mitogens or allogeneic cells, and to increase mononuclear cells' natural killer activity.
    1 context sentence
    Summary · context
    The activity of this compound on peripheral blood mononuclear cells from 12 bone marrow recipients was studied in vitro.
  4. 04LabEx vivo tissueActivity measurement

    In bone marrow recipients' mononuclear cells, thymulin increased natural killer activity.

    In plain wordsIn lab tests, thymulin increased natural killer activity in bone marrow recipients' cells.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    IncreaseNatural killer activity
    Study

    humann = 12

    peripheral blood mononuclear cells from bone marrow recipients
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    It was demonstrated that thymulin was able to induce or modulate the expression of T-cell membrane markers, to enhance the proliferative responsiveness of lymphocytes to mitogens or allogeneic cells, and to increase mononuclear cells' natural killer activity.
    1 context sentence
    Summary · context
    The activity of this compound on peripheral blood mononuclear cells from 12 bone marrow recipients was studied in vitro.

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 05HumanEndogenous levelObservational studyOther

    In bone marrow recipients, serum FTS levels transiently decreased during cellular responsiveness to thymulin in vitro.

    In plain wordsIn bone marrow recipients, natural FTS levels temporarily decreased while their cells responded to thymulin in lab tests.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    DecreaseSerum FTS levels
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    This in vitro responsiveness was contemporary to a transient decrease of FTS levels in the patients' serum, documented by sequential assays.
    1 context sentence
    Summary · context
    The activity of this compound on peripheral blood mononuclear cells from 12 bone marrow recipients was studied in vitro.

    This result measures the body's own Thymulin (serum thymic factor). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.